Influenza Virus

<p>Anti-Influenza agent 4 selectively inhibits A/Parma (EC50: 62 nM) and A/Roma (EC50: 150 nM) influenza strains.</p>

<p>NS1-IN-1: Potent NS1 inhibitor, antiviral, reduces viral proteins by inhibiting mTORC1 via TSC1-TSC2, limits replication.</p>

<p>Laninamivir Octanoate Monohydrate is a neuraminidase inhibitor.</p>

<p>LNK754 is a farnesyltransferase inhibitor. It is used for the treatment of cancer and Alzheimer's disease.</p>

<p>Antiviral agent 43 (compound 16) serves as a potent, orally active inhibitor of influenza A virus entry, demonstrating efficacy by inhibiting the replication of the influenza A strains VH04-H5N1 and PR8-H1N1 with EC50 values of 240 nM and 72 nM, respectively [1].</p>

<p>Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN) and shows research potential against influenza virus infection (</p>

<p>Influenza virus-IN-6 (Compound 35) serves as a potent inhibitor targeting the N-terminal domain of the polymerase acidic protein (PA N ) endonuclease subunit of</p>

<p>L-742001 Hydrochloride is an RNA polymerase inhibitor.</p>

<p>DU-34569 Maleate, an antiviral agent, acts against influenza A, parainfluenza Sendai, coxsackie A21, and rhinovirus.</p>

<p>RO-7 is a next-generation polymerase (PA) endonuclease influenza A and B viruses inhibitor.</p>

<p>JNJ4796 is an oral fusion inhibitor that neutralizes influenza A group 1 by blocking HA-mediated fusion, mimicking bnAbs.</p>

<p>Tirapiravir is an antiviral nucleoside analog that exhibits activity against both the novel coronavirus and influenza virus [1].</p>

<p>EHNA hydrochloride is a PDE2 and ADA inhibitor with anticancer activity, increasing intracellular adenosine concentration in a treatment time-dependent manner.</p>

<p>Antiviral agent 35 (compound 4d) serves as a potent orally active inhibitor of the influenza virus, targeting early stages of viral replication.</p>

<p>XSJ2-46, a 5'-amino NI analog, is an antiviral agent possessing anti-Zika virus properties and demonstrates reasonable inhibition of RNA-dependent RNA</p>

<p>3,4'-Dihydroxyflavone (3,4'-DHF) is an oral active flavonoid. 3,4'-Dihydroxyflavone (3,4'-DHF) shows antiviral activity against Influenza A virus.</p>

<p>3M-011: potent TLR7/8 agonist, cytokine inducer, enhances radiotherapy, fights H3N2, and has anti-tumor effects.</p>

<p>EBOV-IN-1 is an adamantane dipeptide piperazine inhibitor of Ebola virus (EBOV) that inhibits EBOV infection and suppresses pseudotypic EBOV infection.</p>

<p>Massarilactone H, a polyketide, is a neuraminidase inhibitor, with an IC 50 of 8.18 µM .</p>

<p>Flutimide: Endonuclease inhibitor, IC50 = 3μM, for research on acute respiratory diseases like influenza.</p>

<p>Saussureamine C is an inhibitor of H274Y and N294S mutants.</p>

<p>Neuraminidase-IN-11 (15e) inhibits H1N1 (IC50: 4.7nM), H5N1 (8.46nM), H5N8 viruses (1.5nM) selectively &amp; potently.</p>

<p>Neuraminidase-IN-4 inhibits neuraminidase (EC50: 1.59 μM) and has strong anti-H5N1 activity.</p>

<p>Carbodine is an antiviral targeting CTP synthetase, effective against influenza A0/PR-8/34 and A2/Aichi/2/68.</p>

<p>RdRP-IN-5 (compound 20), a potent inhibitor of the influenza virus RNA-dependent RNA polymerase (RdRP), has potential application in influenza research [1].</p>

<p>CEN inhibitor IN-17 targets influenza A/H3N2; IC50: 1.29 μM. From patent CN112898346A, DSC701.</p>

<p>UNC0638 hydrate selectively inhibits G9a and GLP histone methyltransferases with IC50 values of 15 nM and 19 nM, respectively. It is effective in inhibiting invasion and migration of TNBC cells in vitro. Additionally, UNC0638 hydrate acts as an inhibitor of EHMT1/2 and induces the expression of fetal hemoglobin (HbF) in cultures of human erythroid progenitor cells. Furthermore, it exhibits antiviral activity against FMDV (foot-and-mouth disease virus) and VSV (vesicular stomatitis virus), demonstrating remarkable potency and selectivity across various epigenetic and non-epigenetic targets.</p>

<p>Laninamivir trifluoroacetate, a long-acting antiviral, treats and prevents Influenza A and B via nasal spray.</p>

<p>Neuraminidase-IN-18 (compound N5), a novel polyheterocyclic neuraminidase (NA) inhibitor, demonstrates significant inhibitory activity against H5N1 NA, with an IC 50 of 0.14 μM against the wild-type H5N1 NA and 0.27 μM against the H5N1-H274Y mutant NA. This compound effectively binds to NAs, inhibiting influenza virus replication at the cellular level [1].</p>

<p>AV-5080 is an orally active neuraminidase (neuraminidase) inhibitor that is utilized in the research of both Type A and Type B influenza viruses.</p>

<p>VV261 is an orally active inhibitor of the Influenza Virus. It exhibits activity against the Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) and the Lymphocytic Choriomeningitis Virus (LCMV), with EC50 values of 0.89 and 0.15, respectively.</p>

<p>Cap-dependent endonuclease-IN-5 inhibits CEN and fights influenza with low toxicity and good in vivo properties.</p>

<p>Cis-RdRP-IN-5 is an effective inhibitor of the influenza virus RNA-dependent RNA polymerase (RdRP), employed in influenza virus research.</p>

<p>Compound 11h: Potent, low-toxicity anti-influenza, inhibits M2 ion channels. EC50: 3.29μM (H3N2), 2.45μM (H1N1).</p>

<p>Cap-dependent endonuclease-IN-10, with low toxicity &amp; good stability, effectively inhibits flu viruses and shows promise against A, B, C types.</p>

<p>Cap-dependent endonuclease-IN-2 strongly blocks influenza A virus RNA polymerase; it's a CEN inhibitor.</p>

<p>RdRP-IN-4, an oral arylbenzohydrazide, inhibits influenza A/B by targeting PB1 of RdRP, with EC50s of 53 nM (H1N1) and 20 nM (Flu B), and aids infected mice.</p>

<p>Cap-dependent endonuclease-IN-6 (compound 13) is a Cap-dependent endonuclease (CEN) inhibitor that inhibits influenza virus.</p>

<p>Trans-RdRP-IN-5 is a potent inhibitor of the influenza virus RNA-dependent RNA polymerase (RdRP), with applications in influenza virus research.</p>

<p>Cap-dependent endonuclease-IN-7, a potent CEN inhibitor, blocks viral mRNA synthesis and virus spread, with research use for influenza A, B, C.</p>

<p>Cap-dependent endonuclease-IN-14 hinders CEN and could treat influenza virus infections. (Patent CN113620948A, compound 1-c).</p>

<p>Cap-dependent endonuclease-IN-25 is a potent inhibitor of CEN, useful in studying Orthomyxoviridae viruses. (See WO2020075080A1, compound 4.)</p>

<p>Cap-dependent endonuclease-IN-1: potent, oral inhibitor with antiviral properties against influenza.</p>

<p>UH15-38 is a potent and selective RIPK3 inhibitor that blocks necroptosis in alveolar epithelial cells triggered by IAV, useful for studying lung inflammation.</p>

<p>FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola</p>

<p>Cap-dependent endonuclease-IN-9, a strong influenza inhibitor, shows low toxicity, good pharmacokinetics, and dynamic action.</p>